-
EP3250691
European procedure
Extract from the Register of European Patents
EP About this file: EP3250691
| EP3250691 - CRISPR HYBRID DNA/RNA POLYNUCLEOTIDES AND METHODS OF USE [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 27.04.2024 Database last updated on 01.04.2026 | |
| Former | The patent has been granted Status updated on 19.05.2023 | ||
| Former | Grant of patent is intended Status updated on 02.05.2023 | ||
| Former | Examination is in progress Status updated on 15.06.2018 | ||
| Former | Request for examination was made Status updated on 03.11.2017 | ||
| Former | The international publication has been made Status updated on 04.08.2017 | Most recent event Tooltip | 27.04.2024 | No opposition filed within time limit | published on 29.05.2024 [2024/22] | Applicant(s) | For all designated states Caribou Biosciences, Inc. 2929 7th Street Suite 105 Berkeley, CA 94710 / US | [2021/16] |
| Former [2017/49] | For all designated states Pioneer Hi-Bred International, Inc. 7100 N.W. 62nd Avenue P.O. Box 1014 Johnston, Iowa 50131 / US | Inventor(s) | 01 /
MAY, Andrew P. 564 29th Avenue San Francisco, California 94121 / US | 02 /
DONOHOUE, Paul D. San Francisco, California 94103 / US | [2023/25] |
| Former [2017/49] | 01 /
MAY, Andrew P. 564 29th Avenue San Francisco, California 94121 / US | ||
| 02 /
DONOHOUE, Paul D. 1404 Spruce Street Berkeley, California 94709 / US | Representative(s) | Grund, Martin Grund Intellectual Property Group Patentanwälte und Solicitor PartG mbB Steinsdorfstraße 2 80538 München / DE | [2023/25] |
| Former [2017/49] | Dzieglewska, Hanna Eva Dehns St Bride's House 10 Salisbury Square London EC4Y 8JD / GB | Application number, filing date | 16704978.2 | 27.01.2016 | [2017/49] | WO2016US15145 | Priority number, date | US201562108931P | 28.01.2015 Original published format: US 201562108931 P | US201562251548P | 05.11.2015 Original published format: US 201562251548 P | [2017/49] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016123230 | Date: | 04.08.2016 | Language: | EN | [2016/31] | Type: | A1 Application with search report | No.: | EP3250691 | Date: | 06.12.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 04.08.2016 takes the place of the publication of the European patent application. | [2017/49] | Type: | B1 Patent specification | No.: | EP3250691 | Date: | 21.06.2023 | Language: | EN | [2023/25] | Type: | B9 Corrected patent specification | No.: | EP3250691 | Date: | 02.08.2023 | [2023/31] | Search report(s) | International search report - published on: | EP | 04.08.2016 | Classification | IPC: | C12N15/113, C12N15/11, C12N9/22, C12N15/63 | [2023/15] | CPC: |
C12N9/16 (EP,GB,IL,RU,US);
C12N15/907 (IL,KR,RU,US);
C12N15/63 (EP,GB,IL,KR,RU,US);
C12N15/113 (EP,CN,IL);
C12N15/111 (EP,GB,IL,KR,RU,US);
C12N15/102 (CN,GB,IL,KR);
C12N15/82 (GB,IL);
C12N15/8213 (IL,KR,RU,US);
C12N15/902 (CN,GB,IL,KR,RU,US);
C12N9/22 (EP,CN,GB,IL,KR,RU,US);
C12Q1/6827 (IL,KR,RU,US);
C12Y301/00 (EP,GB,IL,RU,US);
C12N2310/10 (IL);
C12N2310/20 (EP,CN,GB,IL,KR,US);
C12N2310/531 (CN,IL);
| C-Set: |
C12N2310/322, C12N2310/3531 (EP)
|
| Former IPC [2017/49] | C12N15/11, C12N9/22, C12N15/63 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/49] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | HYBRIDE CRISPR-DNS/RNS-POLYNUKLEOTIDE UND VERFAHREN ZUR VERWENDUNG | [2017/49] | English: | CRISPR HYBRID DNA/RNA POLYNUCLEOTIDES AND METHODS OF USE | [2017/49] | French: | POLYNUCLÉOTIDES ADN/ARN CRISPR HYBRIDES ET LEURS PROCÉDÉS D'UTILISATION | [2017/49] | Entry into regional phase | 03.08.2017 | National basic fee paid | 03.08.2017 | Designation fee(s) paid | 03.08.2017 | Examination fee paid | Examination procedure | 03.08.2017 | Examination requested [2017/49] | 03.08.2017 | Date on which the examining division has become responsible | 07.11.2017 | Amendment by applicant (claims and/or description) | 14.06.2018 | Despatch of a communication from the examining division (Time limit: M04) | 17.10.2018 | Reply to a communication from the examining division | 28.11.2018 | Despatch of a communication from the examining division (Time limit: M06) | 05.07.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 10.09.2019 | Reply to a communication from the examining division | 16.07.2020 | Despatch of a communication from the examining division (Time limit: M04) | 17.11.2020 | Reply to a communication from the examining division | 07.07.2021 | Despatch of a communication from the examining division (Time limit: M04) | 18.10.2021 | Reply to a communication from the examining division | 08.03.2023 | Cancellation of oral proceeding that was planned for 04.04.2023 | 04.04.2023 | Date of oral proceedings (cancelled) | 03.05.2023 | Communication of intention to grant the patent | 12.05.2023 | Fee for grant paid | 12.05.2023 | Fee for publishing/printing paid | 12.05.2023 | Receipt of the translation of the claim(s) | Divisional application(s) | EP23176464.8 / EP4257690 | Opposition(s) | 22.03.2024 | No opposition filed within time limit [2024/22] | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 10.09.2019 | Request for further processing filed | 10.09.2019 | Full payment received (date of receipt of payment) Request granted | 20.09.2019 | Decision despatched | Fees paid | Renewal fee | 29.01.2018 | Renewal fee patent year 03 | 28.01.2019 | Renewal fee patent year 04 | 27.03.2020 | Renewal fee patent year 05 | 27.01.2021 | Renewal fee patent year 06 | 27.01.2022 | Renewal fee patent year 07 | 27.01.2023 | Renewal fee patent year 08 | Penalty fee | Additional fee for renewal fee | 31.01.2020 | 05 M06 Fee paid on 27.03.2020 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A] WO2014093712 (BROAD INST INC et al.) | [XPA] WO2015026885 (PIONEER HI BRED INT et al.) | [AP] BERND ZETSCHE ET AL: "Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System", CELL, vol. 163, no. 3, 25 September 2015 (2015-09-25), US, pages 759 - 771, XP055267511, ISSN: 0092-8674, DOI: 10.1016/j.cell.2015.09.038 DOI: http://dx.doi.org/10.1016/j.cell.2015.09.038 | [AP] SERGEY SHMAKOV ET AL: "Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems", MOLECULAR CELL., vol. 60, no. 3, 22 October 2015 (2015-10-22), US, pages 385 - 397, XP055267512, ISSN: 1097-2765, DOI: 10.1016/j.molcel.2015.10.008 DOI: http://dx.doi.org/10.1016/j.molcel.2015.10.008 | Examination | WO2014144761 | KIM HANSEOP ET AL: "Enhancement of target specificity of CRISPR-Cas12a by using a chimeric DNA-RNA guide", NUCLEIC ACIDS RESEARCH, vol. 48, no. 15, 4 September 2020 (2020-09-04), GB, pages 8601 - 8616, XP055824405, ISSN: 0305-1048, DOI: 10.1093/nar/gkaa605 [T] DOI: http://dx.doi.org/10.1093/nar/gkaa605 | DONOHOUE PAUL ET AL: "Conformational Control of Cas Endonucleases by CRISPR Hybrid RNA- DNA Guides Mitigates Off-Target Activity in T Cell Editing", 25TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY, 19 May 2022 (2022-05-19), Washington, pages 1 - 1, XP055954925, Retrieved from the Internet | MITCHELL R. O'CONNELL ET AL: "Programmable RNA recognition and cleavage by CRISPR/Cas9", NATURE, vol. 516, no. 7530, 28 September 2014 (2014-09-28), pages 263 - 266, XP055168138, ISSN: 0028-0836, DOI: 10.1038/nature13769 DOI: http://dx.doi.org/10.1038/nature13769 | by applicant | US5049386 | US4946787 | US4897355 | WO9117424 | WO9116024 | US4186183 | US4217344 | US4235871 | US4261975 | US4485054 | US4501728 | US4774085 | US4837028 | US2005257289 | US7256322 | ISHINO ET AL., JOURNAL OF BACTERIOLOGY, vol. 169, no. 12, 1987, pages 5429 - 5433 | MAKAROVA ET AL., NATURE REVIEWS MICROBIOLOGY, vol. 13, 2015, pages 1 - 15 | SHMAKOV ET AL., MOLECULAR CELL, vol. 60, no. 3, 2015, pages 385 - 397 | ZETSCHE ET AL., CELL, vol. 163, no. 3, 2015, pages 759 - 71 | CRYSTAL, SCIENCE, vol. 270, 1995, pages 404 - 410 | BLAESE ET AL., CANCER GENE THER., vol. 2, 1995, pages 291 - 297 | BEHR ET AL., BIOCONJUGATE CHEM., vol. 5, 1994, pages 382 - 389 | REMY ET AL., BIOCONJUGATE CHEM., vol. 5, 1994, pages 647 - 654 | GAO ET AL., GENE THERAPY, vol. 2, 1995, pages 710 - 722 | AHMAD ET AL., CANCER RES., vol. 52, 1992, pages 4817 - 4820 | JINEK ET AL., SCIENCE, vol. 337, no. 6096, 2012, pages 816 - 21 | CHYLINSKI, RNA BIOL, vol. 10, no. 5, 2013, pages 726 - 37 | SVITASHEV, PLANT PHYSIOL, vol. 169, no. 2, 2015, pages 931 - 945 | ANANIEV, CHROMOSOMA, vol. 118, no. 2, 2009, pages 157 - 77 |